Babylat - Corporate Presentation - Test for video

[Audio] This is our training video, where we will be discussing the topic of "Born Early. Nourished Naturally." The presentation is brought to you by Babylat AG, and we are eager to share our insights and knowledge with you. As we explore this topic, we request that you approach it with an open mind and be prepared to learn about the most recent advancements in the field. So let's begin and delve into the world of natural nourishment. This is the first of 23 slides, so let's get started!.

BACKGROUND INFORMATION. © Babylat AG Confidential & Proprietary.

[Audio] In this slide, we will be discussing the importance of early nutrition in shaping future outcomes for brain and cognitive development. Research has shown that daily fortification of milk with extra proteins for 2-3 months can have a significant impact on a child's development. This can be achieved through the addition of essential nutrients and minerals to the milk. It is also important to note that while mother's milk is beneficial, it may not provide enough protein for a baby's daily needs, as it only provides about 25% of the required amount. This highlights the need for human milk enrichment to ensure that babies receive the necessary nutrients for optimal growth and development. Let us remember the importance of early nutrition for the long-term well-being of our children as we continue with our presentation on slide number 4..

[Audio] On slide 4, our discussion of early born babies and natural nourishment brings us to the importance of fortifiers in their nutrition. The use of fortifiers in neonatal care will be the focus of today's presentation, specifically their impact on premature infants. The two types of fortifiers, highly processed bovine milk-derived (BMDF) and highly processed human milk-derived (HMDF), are outlined in purple text on a white background. Research has shown that BMDF can lead to increased risks of gastrointestinal issues, including a serious condition known as necrotizing enterocolitis. Furthermore, studies have found a higher incidence of feeding intolerance with BMDF compared to human milk-based fortifiers. In contrast, HMDF is more costly and presents operational difficulties. Additionally, the lack of transparency around donor information can be a concern for some neonatal care facilities. In the following slides, we will delve deeper into the specifics of both types of fortifiers and their impact on the health and well-being of premature infants. Our aim is to offer a complete understanding of the benefits and drawbacks of each type, enabling you to make informed decisions and provide the best care for these vulnerable babies..

[Audio] Premature babies face numerous challenges on their journey towards a healthy life. These challenges include a high risk of serious complications such as Necrotizing enterocolitis (NEC), sepsis, pneumonia, lung disease, feeding difficulties, and neurodevelopmental issues. However, there is hope in the form of human milk. Human milk contains essential bioactive compounds that boost immune function, support the growth of healthy gut bacteria, and aid in critical organ development. This significantly reduces the risk of NEC, lowers infection rates, and improves lung and brain health. Therefore, it is crucial to prioritize breastfeeding and human milk fortification for preterm infants. By providing them with the necessary support, we can protect them and promote their optimal growth and development..

INTRODUCING BABYLAT. © Babylat AG Confidential & Proprietary.

[Audio] We will now discuss the use of low-temperature ultrafiltration to enrich breast milk for preterm infants. This method is a safe and effective way to provide necessary nutrients for infants who may not be receiving enough through their mother's milk. The process can be done on-site at hospitals or milk banks, guaranteeing the safety and quality of the milk. Enriched breast milk can have significant benefits for preterm infants, eliminating the need for fortifiers derived from bovine milk and reducing the risk of potential health issues. The white machine with a screen on the slide represents this process of low-temperature ultrafiltration, making it a convenient option for hospitals and milk banks. Overall, this method is a natural and effective way to provide the best nutrition for preterm infants, supporting their growth and development..

[Audio] We are currently on slide number 8, where we will be discussing superior nutrition delivery for preterm infants. Our focus is on "Born Early. Nourished Naturally," presented by Babylat AG. On this slide, you will see a table showing data on nutrient levels in normal milk and Babylat HMDF milk. The first column displays levels before enrichment, while the second column shows levels after enrichment. There is a significant increase in proteins, fats, energy, and carbohydrates after the enrichment process, indicating a remarkable improvement in the nutritional value of Babylat HMDF milk. This milk also offers up to 5 daily portions per cycle, making it a time- and cost-effective solution for preterm infants. Additionally, it is processed safely at a temperature range of 2-4°C to ensure strict hygiene. What's more, it only takes 48 hours for the milk to reach the baby from the mother, making it the quickest cycle available. Overall, Babylat HMDF is not just regular milk, it is a powerful solution for the optimal nutrition and growth of preterm infants. Thank you for listening, and let's move on to the next slide..

[Audio] In this slide, we will discuss the four key foundations of Babylat AG's commitment to natural nourishment for premature babies. These foundations serve as the basis for our approach to providing the best possible care and support for these little ones, ensuring they have a healthier, more natural start in life. The first foundation is our innovative technology, constantly evolving to meet the unique needs of premature babies and producing the purest and most natural forms of nutrition for them. Our team of experts is dedicated to researching and developing advanced methods for natural nourishment, using the latest scientific advancements to provide the highest quality products for our babies. Our partnerships with medical professionals and other organizations in the healthcare industry enable us to provide the best care and support for premature babies with a holistic and natural approach. Lastly, we are committed to sustainability and strive to minimize negative impact on the environment through our production processes and materials. These four foundations showcase our dedication to natural nourishment for premature babies, and we are determined to provide the best start in life for all premature babies through our commitment to natural care. Thank you for tuning in, and we look forward to sharing more with you in the future..

[Audio] Slide number 10 displays a table containing data on the patent families for the "Born Early. Nourished Naturally" presentation. The table includes information on geographies, filing dates, reference numbers, and statuses of each patent family. The first patent, filed in the USA in January 2020 with reference number US-84273-20001.001, has been accepted and is currently active from November 2024. In Switzerland, a patent was filed in July 2022 with reference number CH000829/2022 and is also accepted and active from September 2024. In Europe (EPO), a patent was filed in July 2023 with reference number EP23184820 and is currently active. A patent filed in Germany in December 2022 with reference number 120215433400DE is currently pending. The USA has two additional pending patents, one filed in July 2023 with reference number US-84273-20002.00 and the other filed in January 2024 with reference number US-84273-30003.00. The final patent, filed under the PCT in January 2025 with reference number 222730PWO, is also currently pending. These patent families are crucial in protecting the concept, first proof of concept of the device, and final market product for our "Born Early. Nourished Naturally" presentation..

[Audio] Slide 11 out of 23 examines the landscape and provides valuable insights into the challenges that premature babies face. This has led us, at Babylat AG, to create a natural solution for nourishing premature babies. Our thorough landscape analysis has revealed that there is a lack of options available in the market for natural nourishment. This is where Babylat AG can make a difference. Our research has also shown a growing demand from both parents and healthcare professionals for a natural and reliable option for nourishing premature babies. Our expertise and innovation have enabled us to develop a product that not only fills the gap in the market, but also meets the needs and expectations of all stakeholders. Our commitment to confidentiality and proprietary methods ensures that our product is of the highest quality and remains a valuable resource for those who use it. With our gained perspectives, we are ready to move forward and make a positive impact on the health of premature babies. We invite you to join us on this journey and stay tuned for the rest of our presentation as we dive deeper into our natural nourishment solution..

[Audio] Slide 12 discusses the differences between bovine milk-derived fortifiers and premium human-milk derived fortifiers. Bovine milk-derived fortifiers are a cost-effective option for preterm infants, with a daily cost of $10 per baby. However, they have been associated with a higher risk of complications and raised concerns for parents, leading to numerous lawsuits in 2024-2025. On the other hand, premium human-milk derived fortifiers offer exceptional nutritional value but come at a significantly higher cost of $300 per day per baby. Additionally, they are highly processed and expensive, sourced from donors with unclear profiles, which may compromise the original milk's properties and raise ethical concerns. Introducing Ni-Q's HDM Boost™, a shelf-stable, human-donated breast milk product that offers exceptional nutrition and comes in ultra-safe packaging. It provides the best of both worlds for at-risk preterm infants. Visit Ni-Q's website to learn more about their mission of providing high-quality, affordable human milk products..

[Audio] Slide number 13 of our presentation will focus on the importance of mother's milk and its origin, as well as other considerations for nourishing premature infants. The table on this slide contains valuable data on this topic. Firstly, there is a comparison between mother milk-origin and human milk-origin. Mother's milk is known to be the most natural and beneficial source of nutrients for newborns. However, when this is not possible, human milk-origin products are a close alternative. Next, the point of care production method allows for a more controlled and safe production of human milk products, ensuring that each batch is free from any potential harmful substances. One important factor to consider is the immunoactive properties of these milk products. Human milk contains vital immune-boosting factors that are crucial for the health of premature babies. Liquid human milk products also have no risk of pellets or solid chunks, making it a safe and convenient option for feeding. These products have a high concentration of essential nutrients, ensuring proper growth and development for premature babies. The option for on-site production allows for a timely and efficient supply of fresh and safe milk products for premature infants. It is crucial to choose trusted brands such as Cow & Gate™, Medolac Laboratories, Prolacta, and Ni-Q, who prioritize the health and safety of these vulnerable infants. Our next discussion will focus on the cost and accessibility of human milk products..

[Audio] Slide 14: There is a high global demand for specialized nutrition. In our rapidly growing world, this demand is increasing rapidly. The number of preterm infants born each year exceeds 15 million, making proper nourishment more important than ever. Infants with very low birthweight, less than 1.5 kg, require even more specialized nutrition. However, common cow milk fortifiers can cause serious health risks for these fragile babies. This has led to an increase in lawsuits against the safety of cow milk, with over 1000 cases in the US alone. This highlights the need for a safer alternative. Babylat's human milk-derived fortifier is not only a safer option, but also offers significant cost savings. The average cost per baby per day for current fortifiers is $250-$300, while Babylat reduces this cost by more than 60%. Not only is Babylat cost-effective, it is also environmentally friendly. By eliminating the use of water and reducing CO2 emissions associated with producing cow milk-derived fortifiers, Babylat is a more sustainable and eco-friendly choice. In conclusion, the high global demand for specialized nutrition, coupled with the need for a safer and more cost-effective option, make Babylat's human milk-derived fortifier the ideal choice for nourishing premature infants. Babylat is the future of infant nutrition..

[Audio] Slide 15 out of 23: "Born Early. Nourished Naturally." Today, we will be discussing the global costs associated with preterm and very low birth weight infants in the NICU. The average NICU stay for VLBW infants is 54 to 70 days, with an average daily NICU cost ranging from €850 to €4,380 in Europe and $3,500 to $4000 in the USA. However, these costs extend beyond the NICU stay. For VLBW infants, the hospital cost can range from $34000 to $110000 in the USA and the annual direct cost in Western Europe can exceed €4,380 per child at age five. This results in a global annual direct hospital cost of preterm birth that exceeds $10 billion USD, which is three times higher than term infants. A European study found that the long-term societal burden of preterm birth includes both indirect and direct costs, reaching a staggering €19,135 per child from birth to age five. This includes healthcare expenses and lost productivity. These costs have a significant impact on families, healthcare systems, and society. However, there is hope. By improving nutrition and reducing the NICU stay by 10%, significant savings can be made. Meta-analyses estimate that this could save at least $8,600 to $24000 per case globally. Additionally, studies have shown that human milk fortification can result in a 50% reduction in necrotizing enterocolitis (NEC) in preterm infants, leading to savings of over $200000 USD per case avoided. This has been observed in Europe, Australia, and Asia, further emphasizing the potential impact of improved nutrition on reducing these costs. In conclusion, providing proper nutrition to preterm and VLBW infants not only improves their health and well-being, but also saves significant costs for families, hospitals, and society. Please stay tuned for the next part of our training video..

[Audio] Being born prematurely presents challenges, including the risk of complications which can lead to a higher cost of healthcare. These complications, such as NEC, sepsis, severe pneumonia, and bronchopulmonary dysplasia, can add an extra $15000 to $200000 to each case globally. The highest costs are seen in the USA and Western Europe. In high-income nations, the direct cost of NEC per case can range from $74000 to $198000 USD, and in the EU it can range from $55000 to $165000 USD. These complications also prolong hospital stays, with major events adding an average of 7 to 14 days in all regions, further increasing costs and risks. At Babylat, our scientific approach and dedication to innovation are aimed at creating more sustainable and resilient healthcare systems. Our mission is to contribute to the well-being of premature babies around the world. Through our focus on natural nourishment and commitment to progress, we are striving towards a brighter future for premature babies..

[Audio] This slide discusses the estimated number of preterm infants globally and the projected market value for Foods for Special Medical Purposes and neonatal and preterm infant enteral feeding devices using Babylat's technology. It is estimated that Babylat's technology is connected to approximately 13-14 million preterm infants each year worldwide, showcasing the extensive reach and potential of our technology in improving the well-being of preterm infants. The market for Foods for Special Medical Purposes, designed specifically for the dietary management of preterm and low birthweight infants, was valued at $346 million USD in 2024 and is expected to more than double to $825 million USD by 2032 with a strong compound annual growth rate of 13.5%. This highlights the increasing demand and potential for our products in this specialized market. The larger market for neonatal and preterm infant enteral feeding devices, valued at over $3.5 billion USD in 2024, is projected to grow to more than $5.1 billion USD by 2031, with a compound annual growth rate of 5.6%. This growth can be attributed to the rising rate of preterm births and advancements in neonatal care technology. These statistics demonstrate the great potential of Babylat's technology to positively impact the lives of preterm infants and their families, while also presenting growth opportunities for the company..

[Audio] Slide number 18 out of 23 in our presentation on "Born Early. Nourished Naturally" focuses on the Babylat human milk enricher device. This slide features a purple text on a white background and contains the information "preencoded.png". The selling price of the device is $30000 USD, significantly higher than its production cost of $12000 USD. The device has a 40% cost of goods sold and a 60% margin. It is protected by active patents in Switzerland and the United States. In terms of revenue, the Babylat human milk enricher device contributes 30% to our total revenue. We also have the Babylat consumable filter-set, a single-use product with a selling price of $65 USD and a production cost of $12 USD. This product has a 20% cost of goods sold and an 80% margin. It contributes 70% to our total revenue and is an essential part of our product. Both the device and the filter-set work together to generate revenue and ensure the best possible outcome for our company and customers. We appreciate your attention. The remaining slides of our presentation will continue to discuss the Babylat human milk enricher device and its impact on the healthcare industry. This concludes slide number 18..

[Audio] Slide 19 displays a table containing data on the annual quantity of low birth weight (LBW) infants and the corresponding reduction in economic burden for different regions and countries. The figures reveal that the United Kingdom, France, Italy, and Spain have a relatively low number of LBW infants, resulting in economic burden reductions of 1,600 million USD, 1,440 million USD, 1,280 million USD, and 960 million USD, respectively. In contrast, India has the highest number of LBW infants, with an estimated 3 million per year, leading to an economic burden reduction of 48000 million USD. China, Indonesia, Brazil, Mexico, USA, and Colombia also have high numbers of LBW infants, resulting in significant economic burden reductions. This data emphasizes the need to address and prevent LBW, as it not only impacts the health and well-being of infants but also has a significant economic impact. By focusing on timely delivery and natural nourishment, we can work towards decreasing the number of LBW infants and the associated economic burden. Let's continue to raise awareness and take action to ensure a healthier future for all..

[Audio] Slide number 20 of our presentation, "Born Early. Nourished Naturally," contains a table featuring important data on the estimated market size for our product. As of August 2025, our company, Babylat AG, has confidential and proprietary information on the annual number of low birth weight neonates in various regions and countries. The purple text on the white background displays the corresponding data for each country. The United Kingdom has an estimated 0.10 million low birth weight neonates, with a market size of 300 million USD. France closely follows with 0.09 million low birth weight neonates and a market size of 270 million USD. India has the highest number of low birth weight neonates in the Asian market, with 3 million, translating to a market size of 9000 million USD. China and Indonesia have 1.20 million and 0.50 million low birth weight neonates respectively, with market sizes of 3,600 million USD and 1,500 million USD. In the South American market, Brazil has an estimated 0.45 million low birth weight neonates and a market size of 1,350 million USD. Mexico and the USA have similar data, with 0.28 million and 0.25 million low birth weight neonates, and market sizes of 840 million USD and 750 million USD respectively. Colombia has an estimated 0.13 million low birth weight neonates, with a market size of 390 million USD, making it a potential market for our product. These numbers emphasize the potential for our product in various regions and the importance of our mission to provide natural nourishment for early-born babies. Our product has the potential to make a positive impact on the health of these vulnerable infants. We hope you will continue to follow our presentation and join us in our discussion of the future goals of our company in the next slide..

JOIN OUR MISSION. © Babylat AG Confidential & Proprietary.

[Audio] We are now at the end of our presentation and will be looking at slide 22. The image on this slide shows a black and white globe with arrows, representing our company's global impact. Moving forward, Babylat AG's future looks promising. By August 2025, we will be launching our first fully automated prototype and regulatory roadmap for our products. Within the next year, we plan to conduct clinical studies and submit our product for approval, making it industrial-ready. In 2024, we will have a manual prototype and our third family of patent applications, as well as conducting in-vitro studies. In 2027, we will start pilot manufacturing and obtain pre-marketing FDA clearance. By 2028, we plan to expand into the Indian market without needing FDA approval as our products are not deemed medical devices. As we continue to grow, in 2029, we will expand our market reach with FDA clearance. To support this growth, we have secured funding of 0.85 million CHF for Pre-Seed, followed by 1.5 million CHF for our Seed round and 4 million CHF for Seria A. Thank you for joining us on this journey towards a healthier and more sustainable future..

[Audio] Welcome to the conclusion of our presentation on "Born Early. Nourished Naturally" by Babylat AG. We hope you have found our journey of exploring the significance of early nutrition for infants to be enlightening and educational. We want to take this opportunity to remind you that Babylat AG is a leading global provider of natural and nourishing products for babies. Our mission is to support the growth and development of every child by offering them the best nutrition from the very beginning of their lives. Our company is based in beautiful Switzerland, specifically at Weyermannsstrasse 36 in the city of Bern. For more information, please visit our website at https://babylat.com/ or contact us at [email protected]. We appreciate you taking the time to watch our presentation and hope you have gained a deeper understanding of the important role of early nutrition in a child's well-being. We encourage you to continue learning and sharing this knowledge with others. Thank you again for your participation and we look forward to seeing you again in the future..